Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.66 |
| ▸ | ACHE | P22303 | 5/20 | 0.66 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.55 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.55 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL519228 | 0.98 | ALDH1A1 (0.69) | ALDH1A1ACHEOPRL1CYP1A2CYP2D6 | |
| SCHEMBL11813176 | 0.92 | OPRL1 (0.65) | ALDH1A1ACHEOPRL1HSD11B1SMN1; SMN2 | |
| SCHEMBL18274478 | 0.85 | ALDH1A1 (0.62) | ALDH1A1ACHEOPRL1CYP1A2CYP2D6 | |
| SCHEMBL11612810 | 0.85 | OPRD1 (0.54) | ALDH1A1ACHEOPRL1CYP1A2CYP2D6 | |
| SCHEMBL5752267 | 0.83 | OPRD1 (0.59) | ALDH1A1ACHEOPRL1HSD11B1SMN1; SMN2 | |
| SCHEMBL2781893 | 0.83 | ALDH1A1 (0.71) | ALDH1A1ACHEOPRL1CYP2D6CYP2C9 | |
| SCHEMBL14593219 | 0.83 | CHRM2 (0.59) | ALDH1A1ACHEOPRL1CYP2D6CYP2C19 | |
| SCHEMBL11108309 | 0.81 | ACHE (0.51) | ALDH1A1ACHEOPRL1CYP1A2CYP2D6 | |
| SCHEMBL16462127 | 0.81 | ALDH1A1 (0.73) | ALDH1A1ACHEOPRL1CYP2D6CYP3A4 | |
| SCHEMBL11263177 | 0.81 | ALDH1A1 (0.62) | ALDH1A1ACHEOPRL1TSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3349581-B1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-10766890-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10766890-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20180265484-A1 | HEPATITIS B CORE PROTEIN MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-09-20 | — | — | US | disclosed |
| EP-3349581-A1 | HEPATITIS B CORE PROTEIN MODULATORS | Assembly Biosciences, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017048962-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017048962-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-7704996-B2 | Compounds and compositions useful as cathepsin S inhibitors | NOVARTIS AG (CH) | 2010-04-27 | — | — | US | disclosed |
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2009-02-19 | — | — | US | disclosed |
| EP-1781623-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | Novartis AG (CH) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018284-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180265484-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | ALDH1A1 4316/4885ACHE 2193/4885OPRL1 2924/4885 |
| US-10766890-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | ALDH1A1 4316/4885ACHE 2193/4885OPRL1 2924/4885 |
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | CTSS, CTSZ, CTSF | ALDH1A1 4107/4885ACHE 1054/4885OPRL1 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.